Abstract:Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell non-Hodgkin lymphomas (B-NHL), B-cell chronic lymphocytic leukemia (CLL), and multiple myeloma and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. Real-time quantitative PCR (RQ-PCR) targeting circulating lymphoma cells is still the gold standard for MRD detection in indolent B-NHL and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). Alternatively, droplet digital PCR (ddPCR) can be used for MRD monitoring in multiple myeloma, mantle cell lymphoma, CLL, and FL with comparable sensitivity, accuracy, and reproducibility.The most broadly applicable MRD target in B-NHL is the junctional regions of the rearranged immunoglobulin heavy (IGH) and light chain genes. Complete and incomplete IGH and additionally IG kappa light chain rearrangements can be used as targets for MRD. Next-generation sequencing (NGS) of IG-rearrangements (IG-NGS) as new sequencing-based technology can overcome the limitation of PCR-based approaches and has a potential for higher sensitivity. Chromosomal translocations like the t(14;18)(q32;q21) translocation associated with IGH::BCL2 fusion in FL and t(11;14)(q13;q32) translocation in MCL leading to the IGH::CCND1 fusion can be used as MRD target in selected lymphoma subtypes. In patients with CLL, both flow-cytometry and RQ-PCR are equally suited for MRD assessment as long as a sensitivity of 10-4 is achieved.MRD diagnostics targeting the IG loci is complex and requires extensive knowledge and experience because the junctional regions of each clonal rearranged gene have to be identified before the patient-specific PCR assays can be designed for MRD monitoring. In addition, the presence and load of somatic hypermutation within the rearranged IGH gene occurring during B-cell development of germinal center and post-germinal center B-cell lymphomas may hamper appropriate primer binding leading to false-negative results. The translocations mentioned above have the advantage that consensus forward primers and probes, both placed in the breakpoint regions of chromosome 18 in FL and chromosome 11 in MCL, can be used in combination with a reverse primer placed in the IGH joining region of chromosome 14. PCR-based methods using allele-specific primers can reach a high sensitivity of up to 10-5. This chapter provides all relevant background information and technical aspects for the complete laboratory process from detection of the clonal IG gene rearrangements and the chromosomal translocations at diagnosis to the actual MRD measurements in clinical follow-up samples of B-NHL. However, it should be noted that MRD diagnostics for clinical treatment protocols has to be accompanied by regular international quality control rounds to ensure the reproducibility and reliability of the MRD results. This is available by the EuroMRD network ( https://euromrd.org ), a subgroup of ESHLO ( https://eslho.org ).

Measurement of BAFF Mrna Expression in Non-Hodgkin Lymphoma Peripheral Blood Cells by Real-Time Fluorescence Quantitative PCR

Quantitative detection of telomere binding factor 2 gene expression in non-Hodgkin lymphoma with a real-time reverse transcription-polymerase chain reaction assay]

The Measurement of HBV DNA in peripheral blood mononuclear cells and its clinical applicability

Measurement of the Mrna Level of Polo-like Kinase 1 in Bronchoscopic Bioptic Specimens by Real-Time Quantitative PCR

[Role of Measuring the Expression Levels of a Proliferation-Inducing Ligand and Its Receptors by Real-Time Fluorescence Quantitative Method in Children with Lymphoma].

[Detecting HB-1 Expression Level in Bone Marrow of Acute Leukemia Patients by Real-Time Fluorescence Quantitative RT-PCR].

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients

Expression of FOXp3 and HLA-B mRNA in peripheral blood mononuclear cells of lymphoma patients

Fluorescence Quantitative PCR Detection of WT1 Gene Expression in Peripheral Blood of Patients with Acute Leukemias and Its Clinical Implications

Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia

Study of Immunoglobulin and T-cell Receptor Gene Rearrangements in Patients with Non-Hodgkin' S Lymphoma

Feasibility and clinical significance of real-time quantitative RT–PCR assay of PML-RARα fusion transcript in patients with acute promyelocytic leukemia

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

[Monitoring Bcr-Abl Mrna Levels by Real-Time Quantitative RT-PCR in Chronic Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation].

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR

[Detection of Common Fusion Transcript Levels in Untreated Leukemia Patients by Real-Time Quantitative RT-PCR Technique].

[Real-Time Quantitative Detection of E2A-PBX1 Fusion Gene in Children with Acute Lymphoblastic Leukemia and Its Clinical Application in Minimal Residual Disease Monitoring].

Quantitative Real-Time PCR Method for Detection of B-Lymphocyte Monoclonality by Comparison of κ and λ Immunoglobulin Light Chain Expression

[Real-Time Quantitative Study of Minimal Residual Disease in Childhood B Cell Acute Lymphoblastic Leukemia].

Real-time Fluorescence Quantitative PCR in Detecting CD58 Gene Expression in PBMC in Patients with HBV Infection

[Comparisons of Conventional and Normalized Calculation of Quantitative Real-Time RT-PCR Detecting PML-RAR Alpha Fusion Gene in Patients with Acute Promyelocytic Leukemia].